Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883267 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL6189730 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL10945773 | 0.80 | GAA (0.48) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL16009653 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL17736226 | 0.78 | ALDH1A1 (0.52) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL18395150 | 0.78 | POLB (0.43) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL16134065 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL2841590 | 0.77 | ALDH1A1 (0.54) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL10948454 | 0.77 | NPC1 (0.56) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL16659617 | 0.77 | CYP3A4 (0.50) | ALDH1A1CYP3A4MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| EP-1472231-A1 | 2'-HALO-3',5'-DIALKOXYPHEN-1'-YL-IMINO-2-IMIDAZOLIDINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF URINARY INCONTINENCE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6703409-B2 | NITROGEN COMPOUNDS SUCH AS 2'-CHLORO-3',5'-DIMETHOXYPHEN-1'-YL -IMINO-2-IMIDAZOLIDINE OR ISOMERS, USED AS PREFERENTIAL ADRENOCEPTOR AGONISTS FOR PREVENTION OF INCONTINENCE; SIDE EFFECT REDUCTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-03-09 | — | — | US | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
| US-20030162822-A1 | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003064398-A1 | 2'-HALO-3',5'-DIALKOXYPHEN-1'-YL-IMINO-2-IMIDAZOLIDINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | WO | disclosed |
| EP-1333028-A1 | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | disclosed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0304057-B1 | Pyridinone derivatives, and agricultural and horticultural fungicidal compositions containing the same | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1994-04-20 | — | — | EP | disclosed |
| EP-0304057-A2 | Pyridinone derivatives, and agricultural and horticultural fungicidal compositions containing the same | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | ALDH1A1 2575/4885CYP3A4 2628/4885MEN1 4287/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885CYP3A4 6/4885MEN1 606/4885 |
| US-20030162822-A1 | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug | ADRA2C, CLIC1, WNK3 | ALDH1A1 1076/4885CYP3A4 214/4885MEN1 1825/4885 |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | ALDH1A1 1012/4885CYP3A4 929/4885MEN1 4187/4885 |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | ALDH1A1 3245/4885CYP3A4 1555/4885MEN1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.